Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRHYAU)

Drug Name
MAZAPERTINE Drug Info
Synonyms
Mazapertine; UNII-N0X1XW704P; CHEMBL10085; N0X1XW704P; 134208-17-6; RWJ-377796; Mazapertine [INN]; AC1L1TZN; AC1Q5K4U; SCHEMBL636631; DTXSID40158594; ZKZFPRUSWCYSGT-UHFFFAOYSA-N; BDBM50029257; L001470; Piperidino[3-[[4-(2-isopropoxyphenyl)piperazino]methyl]phenyl] ketone; 1-[3-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]benzoyl]piperidine; {3-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-phenyl}-piperidin-1-yl-methanone; piperidin-1-yl-[3-[[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]methyl]phenyl]methanone
Cross-matching ID
PubChem CID
60820
CAS Number
CAS 134208-17-6
TTD Drug ID
DMRHYAU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Adrenergic receptor alpha-2C (ADRA2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [2]
Dihydroergocristine DM5SQ1G Alcohol dependence 6C40.2 Approved [3]
Brimonidine DMQLT4N Ocular hypertension 9C61.01 Approved [4]
Amosulalol DML8QSZ Hypertension BA00-BA04 Approved [5]
Amezinium DM6I2WQ Hypotension BA20-BA21 Approved [6]
Propylhexedrine DMTBW2O Obesity 5B81 Approved [7]
Tetrahydrozoline DMT57WC Ocular disease 1F00.1Z Approved [8]
Rilmenidine DM13PQW Hypertension BA00-BA04 Approved [9]
Xylometazoline DMKV32D Allergic rhinitis CA08.0 Phase 4 [10]
TNX-102 DMO1234 Fibromyalgia MG30.01 Phase 3 [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine D3 receptor (D3R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cariprazine DMJYDVK Bipolar disorder 6A60 Approved [12]
Pramipexole DMNMW9R Parkinson disease 8A00.0 Approved [13]
Ropinirole DMA6S1D Parkinson disease 8A00.0 Approved [13]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [14]
P2B-001 DM9PVHX Parkinson disease 8A00.0 Phase 3 [15]
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [16]
ONC201 DMM5SCF Endometrial cancer 2C76 Phase 2 [17]
TAK-906 DMBQD9H Diabetic gastroparesis DA41.00 Phase 2 [18]
GSK598809 DMGU05N Drug abuse 6C4G.1Z Phase 2 [19]
GSK618334 DMJPXZ4 Drug abuse 6C4G.1Z Phase 1 [19]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-2A (ADRA2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lofexidine DM1WXA6 Heroin and opiate withdrawal 6C43 Approved [20]
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [2]
Connexyn DMF29Q5 Attention deficit hyperactivity disorder 6A05.Z Approved [21]
Guanfacine DMPN5IH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [22]
A295 DM55GO2 Aggressive cancer 2A00-2F9Z IND submitted [23]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [24]
DSP-1200 DM4WSHG Depression 6A70-6A7Z Phase 1 [16]
NMI-870 DMU596F Sexual dysfunction HA00-HA01 Discontinued in Phase 2 [25]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [26]
A-80426 DMBC3DG N. A. N. A. Terminated [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-1B (ADRA1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methamphetamine DMPM4SK Anxiety Approved [28]
Propericiazine DME9JNL Psychiatric disorder 6E8Z Approved [29]
Methoxamine DMF5XQH Hypertension BA00-BA04 Approved [30]
Phendimetrazine DM6TS1N Obesity 5B81 Approved [31]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [24]
TIOSPIRONE DME5QDP N. A. N. A. Discontinued in Phase 3 [32]
Sunepitron DM6M8ZX N. A. N. A. Discontinued in Phase 3 [33]
SOU-001 DMPAEK5 Urinary incontinence MF50.2 Discontinued in Phase 2 [34]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [35]
WB-4101 DMQU8B1 N. A. N. A. Terminated [36]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [37]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [38]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [39]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [12]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [40]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [41]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [42]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [43]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [44]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [45]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-2B (ADRA2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [2]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [24]
AGN-199981 DMP5Y1A Neuropathic pain 8E43.0 Phase 2 [46]
INDORAMIN DMNSJFD Hypertension BA00-BA04 Withdrawn from market [36]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [26]
A-80426 DMBC3DG N. A. N. A. Terminated [27]
WB-4101 DMQU8B1 N. A. N. A. Terminated [47]
SK&F-104078 DMRADBU N. A. N. A. Terminated [36]
(+/-)-nantenine DM0L3GE Discovery agent N.A. Investigative [48]
R-226161 DM4BP7S Discovery agent N.A. Investigative [49]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-1D (ADRA1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxazosin DM9PLRH Benign prostatic hyperplasia GA90 Approved [50]
Armodafinil DMGB035 Malignant glioma 2A00.0 Approved [51]
Alfuzosin DMZVMKF Benign prostatic hyperplasia GA90 Approved [52]
Moxisylyte DMFCLYW Erectile dysfunction HA01.1 Approved [53]
Terazosin DM3JCVS Benign prostatic hyperplasia GA90 Approved [54]
Bunazosin DM4I8O7 Glaucoma/ocular hypertension 9C61 Approved [55]
Trimazosin DM1QLST Congestive heart failure BD10 Approved [56]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [24]
DL-017 DMM8GZT Hypertension BA00-BA04 Phase 1 [57]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [58]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine D2 receptor (D2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [59]
Haloperidol DM96SE0 Delirium Approved [60]
Perphenazine DMA4MRX Schizophrenia 6A20 Approved [61]
Perazine DM2AOTZ Psychotic disorder 6A20-6A25 Approved [62]
Domperidone DMBDPY0 Gastrointestinal disease DE2Z Approved [63]
Levodopa DMN3E57 Parkinson disease 8A00.0 Approved [64]
Quetiapine DM1N62C Anorexia nervosa cachexia 6B80 Approved [65]
Pimozide DMW83TP Schizophrenia 6A20 Approved [66]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [67]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [39]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1A receptor (HTR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [13]
Buspirone DMBS632 Anxiety disorder 6B00-6B0Z Approved [68]
OPC-34712 DMHG57U Major depressive disorder 6A70.3 Approved [69]
Vilazodone DM4LECQ Major depressive disorder 6A70.3 Approved [70]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [12]
Gepirone DMGX5Q0 Major depressive disorder 6A70.3 Approved [71]
TERTATOLOL DM2L3D5 Hypertension BA00-BA04 Approved [72]
Urapidil DMD59GI Hypertension BA00-BA04 Approved [73]
Treximet DMU54QB Migraine 8A80 Approved [19]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-1A (ADRA1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SILODOSIN DMJSBT6 Benign prostatic hyperplasia GA90 Approved [74]
NAFTOPIDIL DMQ8R4E Hypertension BA00-BA04 Approved [74]
Tamsulosin DM5QF9V Benign prostatic hyperplasia GA90 Approved [13]
Xatral DMLHOA0 Benign prostatic hyperplasia GA90 Approved [75]
Dutasteride + tamsulosin DM6P8HU Benign prostatic hyperplasia GA90 Phase 3 [19]
Besipirdine DMLVNTA Cognitive impairment 6D71 Phase 3 [76]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [24]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [58]
PMID30124346-Compound-LDT66 DMJMTNL Benign prostatic hyperplasia GA90 Patented [58]
TIOSPIRONE DME5QDP N. A. N. A. Discontinued in Phase 3 [32]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Inhibitor [1]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Inhibitor [1]
Adrenergic receptor alpha-1A (ADRA1A) TTNGILX ADA1A_HUMAN Inhibitor [1]
Adrenergic receptor alpha-1B (ADRA1B) TTBRKXS ADA1B_HUMAN Inhibitor [1]
Adrenergic receptor alpha-1D (ADRA1D) TT34BHT ADA1D_HUMAN Inhibitor [1]
Adrenergic receptor alpha-2A (ADRA2A) TTWG9A4 ADA2A_HUMAN Inhibitor [1]
Adrenergic receptor alpha-2B (ADRA2B) TTWM4TY ADA2B_HUMAN Inhibitor [1]
Adrenergic receptor alpha-2C (ADRA2C) TT2NUT5 ADA2C_HUMAN Inhibitor [1]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Inhibitor [1]
Dopamine D3 receptor (D3R) TT4C8EA DRD3_HUMAN Inhibitor [1]

References

1 A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
2 Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
3 Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
5 Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
6 Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
7 Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
8 Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
9 Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
10 Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
11 Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
12 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
14 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
15 Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
18 Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
19 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
20 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
21 alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
22 Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Apr 7:1-13.
23 Clinical pipeline report, company report or official report of Klus Pharma
24 A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
25 Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
26 Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
27 Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
28 Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9.
29 Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91.
30 Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2.
31 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
32 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
33 An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
34 Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.
35 Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
36 Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
37 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
38 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
39 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
40 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
41 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
42 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
43 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
44 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
45 Clinical pipeline report, company report or official report of Lundbeck.
46 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
47 alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
48 Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
49 Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60.
50 The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
51 Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
52 Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
53 Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
54 Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
55 Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
56 The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
57 Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
58 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
59 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
60 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
61 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
62 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
63 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
64 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
65 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
66 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
67 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
68 Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
69 Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
70 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
71 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
72 Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
73 Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
74 Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
75 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
76 Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.